Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries

Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland

“…This study was conducted across 10 European countries (Belgium, France, Scotland, Spain, Sweden, Denmark, the UK (specifically, England and Wales), Germany, Italy and The Netherlands). 23 These results are consistent with the results of the present analysis and are not surprising since many costly clinical interventions may be avoided due to pneumococcal vaccination. In the present study, PPV23 appears to be more cost-effective than in other countries may be due to our assumption that the NFZ would reimburse only 50% of the vaccine cost, whereas in other countries the full cost is usually reimbursed.…”

“…No correction was made to the overall mortality to account for the fact that this included pneumococcal mortality since this is a relatively rare cause of mortality in the general population. 41 In line with estimates from the WHO and with values observed across Europe, 23,29,42 the incidence of IPD was assumed to be 54.50 per 100,000 in the population aged 65 or older in Poland. From these, 50.41 cases were BPP and 4.09 were PM.…”

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

“…As Postma et al 18 concluded in their literature review published in 2003 on the basis of the international literature in the elderly, the cost-effectiveness for the prevention of invasive pneumococcal disease, considering only direct medical costs, varies from cost-saving to more than €30,000 per LYG or per QALY. 15,[19][20][21][22][23] These results would justify local implementation of a pneumococcal polysaccharide vaccination program from a pharmacoeconomic point of view. In studies concerning both invasive and non invasive pneumococcal …”

A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany

“…The vaccination is well tolerated [4,7,18,19]. Recent economic evaluations showed that vaccinating at-risk adults and the elderly with PPV23 was a cost-effective strategy when compared with no vaccination, even when accounting for the decline in incidence of IPD in adults induced by universal childhood vaccination against pneumococcal diseases [7,[20][21][22][23][24][25][26][27][28][29].…”